Ophthalmic Lasers in California

Stallion Medical, established in 1992 in San Diego, California, is a specialized distributor of ophthalmic equipment and surgical instruments manufactured in stainless steel and titanium. The company serves ophthalmology clinics, hospitals, and eye care facilities with a comprehensive portfolio of diagnostic and surgical ophthalmic devices. Their product range includes portable slit lamps, fundus cameras, tonometers, trial lenses, vision testing systems, indirect ophthalmoscopes, lensmeters, and examination tables. Stallion Medical emphasizes quality assurance, competitive pricing, and innovation in ophthalmic instrumentation. All products are backed by material and manufacturing guarantees and are available through direct purchase with a 30-day return policy.

Norlase ApS is a Danish ophthalmic laser manufacturer specializing in portable, battery-powered laser photocoagulation systems for retinal disease treatment. The company designs and sells compact laser devices that integrate directly into existing clinical workflows, eliminating the need for external consoles, fiber tethers, or wall power. Product lines include LEAF (green laser photocoagulator attachable to slit lamps), LION (battery-powered laser indirect ophthalmoscope with wireless controls and voice activation), ECHO (pattern scanning laser photocoagulator with MEMS technology), and LYNX (pattern scanning laser indirect ophthalmoscope). All products deliver green laser therapy for conditions including age-related macular degeneration, glaucoma, and retinal holes. Norlase emphasizes portability, treatment flexibility, and practice efficiency. The company maintains dual operations in Denmark (headquarters in Ballerup) and the United States (Redwood City, California). Recent news indicates strong global growth (40% install base increase in 2025) and secured €20 million in venture debt financing. Products are marketed with operator manuals, clinical resources, and distributor networks. No specific FDA 510(k), CE, or ISO certifications are mentioned on the homepage, though regulatory references suggest market approval in multiple jurisdictions.

Excel-Lens is a global biotech company specializing in advanced proprietary technologies for cataract surgery. The company develops and manufactures precision surgical devices and solutions designed to assist surgeons in achieving superior outcomes across cataract cases ranging from premium to complex procedures. Primary product offerings include CAPSULBlue® and CAPSULaser®, proprietary technologies that represent the company's core innovation portfolio for ophthalmic surgical applications. Excel-Lens operates directly in the United States and Australia, while leveraging strategic partnerships with world-class distributors internationally. The company positions itself as a developer of precision instruments and technologies that enhance surgical precision and clinical outcomes in cataract management. The website is restricted to healthcare professionals, including surgeons, hospital purchasing officers, government and charitable healthcare administrators, practice managers, and medical device wholesalers.

Aurolab is a global ophthalmic medical device and pharmaceutical manufacturer serving 160+ countries with 200+ solutions across the full continuum of eye care—from diagnosis through treatment and recovery. The company specializes in intraocular lenses (IOLs) for cataract surgery, ophthalmic pharmaceuticals, surgical sutures, surgical blades, diagnostic and surgical equipment, and optical components. Aurolab's product portfolio spans multiple ophthalmic specialties: cataract, retina, cornea, glaucoma, orbit & oculoplasty, and general ophthalmology. The company positions itself as a partner to surgeons and clinicians in high-volume and high-performance surgical settings, providing equipment and consumables designed for real-world clinical practice. Aurolab holds globally recognized certifications (indicated on their website) and demonstrates regulatory compliance. The company manufactures and distributes across all major markets, with a focus on delivering steady, high-quality outcomes at scale. Product lines include IOL systems for cataract interventions, surgical instruments, pharmaceutical formulations across ophthalmologic specialties, and optical devices.

Cortigent, Inc. is a neuromodulation medical device company developing advanced brain implant systems for treating profound blindness and stroke-related paralysis. The company's core technology comprises a proprietary data processing unit that wirelessly controls microelectronic implants containing a unique 60-electrode array positioned on the brain's surface. These electrodes deliver targeted electrical stimulation to specific brain regions to either restore visual perception or enhance motor recovery. Orion® Visual Cortical Prosthesis System is Cortigent's lead product candidate, designed to provide artificial vision to patients with nearly all forms of profound blindness, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye trauma. The Orion system builds upon the legacy of Argus® Retinal Prosthesis System (Argus II), the world's first FDA-approved device for artificial vision in retinitis pigmentosa patients. Cortigent has discontinued Argus II to focus development on Orion, which targets a substantially larger patient population. A second development program addresses motor skill recovery in stroke patients. This neurostimulation system leverages the 60-channel electrode configuration to selectively target motor cortex neurons, intended to enhance hand and arm movement recovery in partially paralyzed stroke victims undergoing rehabilitation. As of January 2026, Cortigent presented promising six-year early feasibility study results for the Orion system at the North American Neuromodulation Society conference. The company is currently a subsidiary of Vivani Medical with active clinical studies recruiting prospective participants. All devices remain in clinical development or early-stage commercialization phases.

Convergent Laser Technologies is a leading manufacturer of medical laser systems and fiber-optic devices for clinical applications. The company specializes in urology, including laser lithotripsy and benign prostatic hyperplasia (BPH) treatment, leveraging proprietary fiber delivery technology to achieve reliable, controlled, and precise power delivery for physician-selected techniques. Key product lines include the Optica XT (stone dusting and soft tissue applications), T-1470 ProTouch and LiteTouch (prostate treatment), and Odyssey 30 systems. Convergent also offers remanufactured fiber solutions designed to reduce procedural costs and environmental impact. Based in Alameda, California, the company serves hospitals and surgical centers with clinical training and field support.